Skip to main content

Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases

Buy Article:

$68.00 + tax (Refund Policy)

The growth factor signals regulate the balance of cell proliferation and cell death to maintain the homeostasis in vivo; hence, deregulation of the balance underlies a variety of human diseases. The PI3K-Akt network is activated by various cytokines or growth factors and mediates intracellular signals to regulate a wide variety of cellular responses, including anti-apoptosis, proliferation, cell cycling, protein synthesis, glucose metabolism, and telomere activity. Genomic mutations, alterations, amplifications, and/or translocations of the oncogenes, tumor suppressor genes, or kinases involved in the PI3K-Akt regulatory network underlie various human diseases such as cancers, viral infections, glucose intolerance (or diabetes mellitus), schizophrenia, and/or autoimmune diseases. Therefore, targeting the PI3K-Akt network becomes an attractive goal for drug development.This review article summarizes the current knowledge about the regulation of the PI3K-Akt signaling network to highlight therapeutic implications for human diseases.





Keywords: Akt; PI3K-Akt network; Phosphoinositide 3 Kinase; cancer therapy; inhibitors; pharmacological compounds

Document Type: Research Article

Publication date: 01 May 2008

More about this publication?
  • In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders.

    The aim of this journal is to publish timely in-depth reviews as well as original papers in the field of signal transduction therapy. Thematic issues will also be published to cover selected areas of signal transduction therapy. Coverage of the field will include genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases.

    Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content